mRNA leading expert Kenneth Chien and Novalis LifeSciences’ Marijn Dekkers invest in EUR 39M Series B2 financing of mRNA technology platform company eTheRNA to expand its expertise and capabilities as a one-stop service to bring RNA-based research and products from the lab to the clinic.
Read the full article on VUB Today
Read the article in De Tijd